We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novo Nordisk | TG:NOV | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.88 | 1.53% | 124.62 | 124.42 | 124.80 | 124.92 | 122.30 | 122.56 | 43,263 | 22:50:06 |
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 2.2 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 7 May 2024 and ending on 5 August 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contact for further information
Media: | |
Ambre James-Brown +45 3079 9289abmo@novonordisk.com | Liz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
Investors: | |
Daniel Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina Meyer +45 3079 6656azey@novonordisk.com | Frederik Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Ida Melvold Gjøsund+45 3077 5649 idmg@novonordisk.com |
Company announcement No 38 / 2024
Attachment
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions